Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,651   4.84  Index Moved Down -0.29%
FNMFO FNMFO 096770 KDDIF Convertibles Marketing Railroads Exotic 
United States GSPC USD ...  |  Company Directory


Processing
Collecting data for SNY and MRK ...

Asset Comparison and Correlation

    
Investment horizon: 
  30 Days    Login   to change
 
 Sanofi  vs   Merck & Co. Inc.
 Compare Fundamentals  
Daily Returns (%)
MRK   SNY   
 
Considering 30-days investment horizon, Sanofi is expected to generate 1.22 times more return on investment than Merck. However, Sanofi is 1.22 times more volatile than Merck Co Inc. It trades about 0.04 of its potential returns per unit of risk. Merck Co Inc is currently generating about -0.11 per unit of risk. If you would invest  5,474  in Sanofi on April 23, 2013 and sell it today you would earn a total of  31.00  from holding Sanofi or generate 0.57% return on investment over 30 days.

Diversification

Very weak diversification
Overlapping area represents amount of risk that can be diversified away by holding Sanofi and Merck & Co. Inc. in the same portfolio assuming nothing else is changed

Correlation Coefficient

0.46
Parameters
Time Period1 Month [change]
DirectionPositive MRK Moved Up vs SNY
StrengthWeak
Accuracy100.0%
ValuesDaily Returns
Follow Correlation between SNY and MRK with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Correlation between SNY and MRK to your reader
 
Share Correlation between SNY and MRK 
Find Opportunities
 
Predicted Return Density
 
Returns   
MRK   SNY   

Sanofi

 
    
Sanofi
Performance
2
Out Of
100
Over 30
Days
98% of all equities and portfolios perform better than Sanofi. Compared with the overall equity markets, risk-adjusted returns on investments in Sanofi are ranked lower than 2 (%) of all global equities and portfolios over the last 30 days.
    

Match ups for Sanofi

Johnson Johnson vs. Sanofi
Pfizer Inc vs. Sanofi
Novartis AG vs. Sanofi
Merck Co Inc vs. Sanofi
GlaxoSmithKline plc vs. Sanofi
BristolMyers Squibb Company vs. Sanofi
AstraZeneca PLC vs. Sanofi
Eli Lilly and Company vs. Sanofi
Impax Laboratories Inc vs. Sanofi
  

Merck Co Inc

 
    
Merck
Performance
0
Out Of
100
Over 30
Days
Over the last 30 days Merck Co Inc has generated negative risk-adjusted returns adding no value to investors with long positions.
    

Match ups for Merck

Johnson Johnson vs. Merck Co Inc
Pfizer Inc vs. Merck Co Inc
Novartis AG vs. Merck Co Inc
Sanofi vs. Merck Co Inc
GlaxoSmithKline plc vs. Merck Co Inc
BristolMyers Squibb Company vs. Merck Co Inc
AstraZeneca PLC vs. Merck Co Inc
Eli Lilly and Company vs. Merck Co Inc
Impax Laboratories Inc vs. Merck Co Inc


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium